Sign In
Buy BLCM
$0.0748
+0 (+0%)
At Close: Jun 03, 2024
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
04:05pm, Tuesday, 30'th Mar 2021
Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2
Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
04:05pm, Tuesday, 23'rd Mar 2021
Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT
BLCM Stock Price Increases Over 15% Pre-Market: Why It Happened
08:21am, Thursday, 04'th Mar 2021
The stock price of Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) has increased by over 15% pre-market. This is why it happened.
BLCM Stock Price Increases Over 40% Pre-Market: Why It Happened
07:38am, Friday, 29'th Jan 2021
The stock price of Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) is trading at over 40% pre-market. This is why it happened.
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
04:05pm, Thursday, 28'th Jan 2021
HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S.
Bet on Rising P/E With These 5 Top-Ranked Stocks
09:47am, Wednesday, 06'th Jan 2021
Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's Why
12:47pm, Friday, 25'th Dec 2020
Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bet on Rising P/E Investing With These Top 5 Stocks
08:17am, Friday, 18'th Dec 2020
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
07:30am, Thursday, 10'th Dec 2020
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
07:30am, Monday, 07'th Dec 2020
HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has be
Is Bellicum Pharmaceuticals Inc (BLCM) A Good Stock To Buy?
04:12pm, Friday, 27'th Nov 2020
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilitie
Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update
04:05pm, Thursday, 05'th Nov 2020
Strategic focus on clinical GoCAR-T ® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year
Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering
08:26pm, Tuesday, 03'rd Nov 2020
HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of
Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market
05:16pm, Thursday, 29'th Oct 2020
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
05:15pm, Thursday, 29'th Oct 2020
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data f
